CNB Bank boosted its position in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 9.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 2,962 shares of the medical research company’s stock after purchasing an additional 263 shares during the period. CNB Bank’s holdings in Charles […]
Shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The […]
Provence Wealth Management Group acquired a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) during the 3rd quarter, HoldingsChannel.com reports. The firm acquired 292 shares of the medical research company’s stock, valued at approximately $57,000. Several other institutional investors and hedge funds have also recently modified their holdings of […]
Charles River Laboratories International (NYSE:CRL – Get Free Report) had its price target lifted by Evercore ISI from $260.00 to $265.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the medical research company’s stock. Evercore ISI’s target price would indicate a potential upside of 8.54% from […]
Bryn Mawr Capital Management LLC cut its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 3.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,809 shares of the medical research company’s stock after […]